Early access
Sign in
Taking people in United StatesPhase 2

Stem cell collection method before transplant in blood cancer patients

Tests G-CSF with selective plerixafor to collect stem cells in adults with myeloma or lymphoma.

Key facts

Who runs it
Thomas Jefferson University
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
16 Oct 2025
Expected to end
Jun 2028
Type of study
Interventional
Treatments tested
  • Plerixafor
  • Gcsf
Record updated
28 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are about to have an autologous stem cell transplant for multiple myeloma, Hodgkin lymphoma or non-Hodgkin lymphoma.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Multiple myeloma, Hodgkin lymphoma or non-Hodgkin lymphoma, with an autologous stem cell transplant planned.
Earlier treatment
People must have had stem cell mobilization with G-CSF (or biosimilars) with plerixafor, or with G-CSF (or biosimilars) alone.

Main reasons for not taking part

  • Uncontrolled HIV
  • Uncontrolled bacterial infection
  • Active CNS disease
  • Pregnancy or breastfeeding
  • Another cancer, except a skin cancer treated only locally

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:; Age ≥18 years; Undergoing autologous stem cell transplant for one of the following diagnoses:; Multiple myeloma; Hodgkin's lymphoma; Non-Hodgkin lymphoma; Karnofsky performance status of ≥ 60%; Patients must meet the TJUH BMT SOP guidelines for "Patient Criteria for Autologous HSCT" as specified below; Adequate organ function:; LVEF of ≥40%; Adjusted DLCO ≥45% of predicted corrected for hemoglobin; Adequate liver function as defined by a serum bilirubin <1.8, AST or ALT < 2.5X upper limit of normal; Serum creatinine ≤ 2.0 mg/dl and/or creatinine clearance of > 40 ml/min (excludes multiple myeloma patients receiving high dose Melphalan conditioning); Willingness to use contraception if childbearing potential; Has the ability to give informed consent, or for cognitively or decisionally impaired individuals (vulnerable population), the availability of a family member or guardian to give consent and assist in the consent process; Life expectancy of > 12 months (exclusive of the disease for which the Auto HSCT is being performed); Patients must have undergone stem cell mobilization with the combination of G- CSF or biosimilars with plerixafor or G-CSF or biosimilars alone

Who cannot take part

  • An individual who meets any of the following criteria will be excluded from participation in this study:; Uncontrolled HIV; Uncontrolled bacterial infection; Active CNS disease; Pregnancy or lactation; Evidence of another malignancy, exclusive of a skin cancer that requires only local treatment

Where in United States

  • Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Xia Bi, MD, MSTaking people

About the trial

What the trial wants to find out

This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome.

Read full original descriptionShow less

The trial aims to evaluate whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome.

The group in the trial

  • Treatment with G-CSF and plerixafor for stem cell mobilizationTreatment being tested

    All patients will receive G-CSF (peg-filgrastim or filgrastim) on day -4 prior to planned peripheral blood stem cell (PBSC) collection day 0. All patients will proceed with stem cell collection on day 0. If less than 1.7 x 106 CD34+ cells/kg is collected after the first day or the target number of stem cells is not collected after two days, Plerixafor will be administered, and additional collection days will be added until the collection goal is reached.

    Treatment: Plerixafor and Gcsf

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective Trial Evaluating Plerixafor-based Mobilization and Risk of Engraftment Syndrome After Autologous Hematopoietic Stem Cell Transplantation
Plain-language title
Stem cell collection method before transplant in blood cancer patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 November 2025